Study In Patients With Kidney Cancer Treated With Sutent
Launched by PFIZER · Mar 30, 2009
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
- Exclusion Criteria:
- • Hypersensitivity to sunitinib malate or to any of the excipients
- • Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Banska Bystrica, , Slovakia
Zilina, , Slovakia
Nitra, , Slovakia
Bratislava, , Slovakia
Presov, , Slovakia
Trencin, , Slovakia
Poprad, , Slovakia
Bojnice, , Slovakia
Kosice, , Slovakia
Michalovce, , Slovakia
Ruzomberok, , Slovakia
Trebisov, , Slovakia
Trnava, , Slovakia
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials